ArticleHaematologica2022

Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results.

Alexander Roth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.